[8-K] Ventyx Biosciences, Inc. Reports Material Event

Rhea-AI Filing Summary

Ventyx Biosciences (VTYX) announced top-line data from its Phase 2 trial of VTX3232, a CNS-penetrant NLRP3 inhibitor, in participants with obesity and cardiovascular risk factors. The company will host a conference call at 4:30pm ET on October 22, 2025 to review the results.

The press release and a topline results presentation are provided as Exhibits 99.1 and 99.2. The information was furnished under Regulation FD and is not deemed filed under Section 18 of the Exchange Act.

false 0001851194 0001851194 2025-10-22 2025-10-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 22, 2025

VENTYX BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-40928		83-2996852
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

12790 El Camino Real Suite 200
San Diego, California		92130
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 760 407-6511

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		VTYX		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On October 22, 2025, Ventyx Biosciences, Inc. (the “Company”), issued a press release announcing top-line data from its Phase 2 trial of its CNS-penetrant NLRP3 inhibitor, VTX3232, in patients with obesity and cardiovascular risk factors. As part of the press release, the Company announced that it would be hosting a conference call at 4:30pm ET on October 22, 2025 to review the study results. The press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Information.

In connection with the conference call to review the Phase 2 trial results, the Company will be reviewing the Phase 2 Trial of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors Topline Results Presentation attached hereto as Exhibit 99.2, which is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated October 22, 2025.
99.2		Phase 2 Trial of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors Topline Results Presentation, dated October 22, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						VENTYX BIOSCIENCES, INC.
Date: October 22, 2025				By:		/s/ Raju Mohan
						Raju Mohan, Ph.D. Chief Executive Officer and Director (Principal Executive Officer)

3

FAQ

What did VTYX announce in this 8-K?

Ventyx Biosciences announced top-line data from a Phase 2 trial of VTX3232 in participants with obesity and cardiovascular risk factors.

What is VTX3232 and what condition was studied?

VTX3232 is a CNS-penetrant NLRP3 inhibitor evaluated in a Phase 2 trial involving participants with obesity and cardiovascular risk factors.

When is VTYX’s conference call to discuss the results?

The company scheduled a conference call for 4:30pm ET on October 22, 2025 to review the study results.

Where can investors find the detailed materials?

The press release is in Exhibit 99.1 and the topline results presentation is in Exhibit 99.2.

Is the information considered filed with the SEC?

No. The information was furnished under Regulation FD (Item 7.01) and is not deemed filed under Section 18 of the Exchange Act.

What exchange does VTYX trade on?

VTYX common stock trades on The Nasdaq Global Select Market.